**Name of journal: *World Journal of Clinical Cases***

**ESPS Manuscript NO: 11896**

**Columns: MINIREVIEW**

**Squamous cell carcinoma of the scrotum: A look beyond the chimneystacks**

Vyas R *et al.* Scrotal squamous cell carcinoma

Ritva Vyas, Homayoun Zargar, Rossella Di Trolio, Giuseppe Di Lorenzo, Riccardo Autorino

**Ritva Vyas,** Department of Dermatology, University Hospitals Case Medical Center, Cleveland, OH 44106, United States

**Homayoun Zargar,** Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OU 44195, United States

**Rossella Di Trolio,** Unit of Medical Oncology and Innovative Therapy, National Cancer Institute “Fondazione Giovanni Pascale”, 80100 Napoli, Italy

**Giuseppe Di Lorenzo,** Genitourinary Cancer Section and Rare-Cancer Center, Medical Oncology Division, University Federico II, 80100 Napoli, Italy

**Riccardo Autorino,** Urology Institute, University Hospitals Case Medical Center, Cleveland, OH 44106, United States

**Riccardo Autorino,** Urology Unit, Second University of Naples, 80100 Naples, Italy

**Author contributions:** All authors contributed to this paper.

**Correspondence to: Riccardo Autorino, MD, PhD, FEBU,** Urology Institute, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44160, United States. [ricautor@gmail.com](mailto:ricautor@gmail.com)

**Telephone:** +1-440-5168700 **Fax:** +1-216-2015276

**Received:** June 11, 2014 **Revised:** August 23, 2014

**Accepted:** September 16, 2014

**Published online:**

**Abstract**

Despite the low incidence, squamous cell carcinoma (SCC) remains the most common scrotal malignancy featuring a propensity for recurrence and metastasis. In recent years there has been a significant change in the epidemiology of scrotal SCC. Surgery is the mainstay of treatment for resectable disease. Sentinel lymph node dissection similar to algorithm for patients with penile SCC can reduce the morbidity of routine lymph node dissection. Emerging treatments for advanced and metastatic SCC are at the cusp of significantly changing management of this disease. We have performed a comprehensive review of scrotal SCC with a focus on these topics.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Squamous cell carcinoma; Genital cancer; Scrotal cancer

**Core tip:** Scrotal squamous cell carcinoma (SCC) although rare, represents one of the most common forms of scrotal malignancy. The epidemiology of SCC has changed over time and iatrogenic conditions (psoralens and ultraviolet A radiation, immunosuppression, *etc.*) and human papilloma virus infection play a significant role as associating conditions. Surgery is the cornerstone of treatment and primary excision with risk stratified approach for staging and treatment of regional lymph node is advisable. Sentinel lymph node biopsy can mitigate the morbidities of unwarranted inguinal lymph node dissection in selected cases. For locally advanced and metastatic disease palliative chemotherapy is advocated. Targeted therapies might hold promise for management of advanced SCC.

Vyas R, Zargar H, Trolio RD, Lorenzo GD, Autorino R. Squamous cell carcinoma of the scrotum: A look beyond the chimneystacks. *World J Clin Cases* 2014; In press

**INTRODUCTION**

Squamous cell carcinoma (SCC) is the most common scrotal malignancy[1,2]. Despite awareness and removal of occupational carcinogens over the last century, after initial reduction in incidence, scrotal SCC has maintained a steady incidence rate. Due to significant associated morbidity and mortality it remains an important urogenital malignancy for the urologist. Our aim was to review recent published literature on scrotal SCC and highlight changing epidemiology as well as emerging therapies.

**HISTORICAL BACKGROUND**

The earliest accounts of scrotal SCC date back to the Persian nomads who used to transport pots of burning coal between their legs to keep warm as they travelled[3]. The first clinical descriptions of cases occurring were by Bassius and Treyling in the mid 1700s, with Treyling describing a case in a Cavalryman[4]. Sir Percival Potts in 1775 was the first to link the chronic lodgment of soot in the rugal folds of the scrotum occurring in chimney sweeps to development of scrotal SCC[5-7]. It hence became known as the first described occupational disease. The active carcinogen discovered later was 3,4-benzpyrene. Occupational scrotal SCC was also later described in association with other occupations with chronic carcinogen exposure including cotton mule spinners, paraffin and tar workers, creosote workers, shale oil workers, lathe workers, pitch workers and machine tool setters and operators[4,8-12]. More recently it has been described in car mechanics, car and airplane manufacture, gas workers, engineers, steel manufacture and aluminum workers[11,13-15]. The majority of occupationally related scrotal SCC can be attributed to exposure to carcinogenic polycyclic aromatic hydrocarbons[10].

**EPIDEMIOLOGY**

In order to assess recent trends in the epidemiology of scrotal SCC, we examined all clinical studies published on scrotal SCC since the year 2000.

There were six case series published including two Surveillance Epidemiology, and End Results (SEER) based analyses, one Netherlands Cancer Registry (NCR) based analysis, one prospective multi-institutional study and two retrospective studies[1,2,16-19].

Studies in the mid-to-late 1900s reported that scrotal SCC accounting for the majority (80%-100%) of all scrotal malignancies but in more recent reports it only accounts for one-third of all scrotal malignancies[1,2,16,20,21]. However scrotal SCC still remains the most common scrotal malignancy[1,2,16]. Other scrotal malignancies include extramammary Paget’s disease (EMPD), sarcoma, basal cell carcinoma, melanoma, Bowen’s disease (SCCIS) and adnexal skin tumors. Median age at diagnosis ranges from 52-57 years[1,18,19]. Most cases occur in Caucasian men followed by Black and Asian men and other ethnicities.

Verhoeven *et al*[1] reported the age-standardized 5-year incidence rate of all histologic types of scrotal cancer in the Netherlands and this varied between 0.9 and 1.8 per 1000000 male person-years from 1986 to 2006 with no statistically significant change over time[1]. Age-standardized incidence rate of scrotal SCC varied between 0.34 and 0.44 per 1000000 male person-years from 1986 to 2006. Over a similar time period Wright *et al*[2] reported on the age-adjusted incidence rate of scrotal cancer in the United states which increased from 0.49 per 1000000 persons in 1973 to 0.95 per 1000000 persons in 2002. While specific incidence rate of scrotal SCC was not provided they did report no change in incidence rates by histologic type[2]. The incidence reported from the Connecticut Tumor registry data from 1935 to 1979 showed stable incidence rates of all scrotal malignancies and epithelial scrotal malignancies[22]. It has been speculated that the reason for this sustained incidence despite occupation carcinogen avoidance has been the emergence of new risk factors such as phototherapy for the treatment of skin diseases and human papilloma virus (HPV).

Johnson *et al*[16] reported on largest SEER series of scrotal squamous cell carcinoma with 269 patients focusing on histologic subtypes. They categorized scrotal SCC, melanoma and adnexal skin tumors as high-risk scrotal SCC and scrotal basal cell carcinoma, EMPD and sarcoma as low-risk based on median overall survival of 118 mo for the high-risk group and 166 mo for the low-risk group[16]. Survival for scrotal SCC was 115 mo (range 97-133), which was the second lowest with lowest being adnexal skin tumors with median overall survival of 114 mo[16]. Wright *et al*[2] reported statistically significant worse survival for those with SCC than for those with other histologic types. SCC comprised 35% of all scrotal tumors in whites compared to 69% in blacks[2]. Dutch researchers reported 77% 5-year survival for scrotal SCC[1].

In early 1990s, Goldolf *et al*[23] reported that the incidence of scrotal SCC despite increase in the rates of UV exposure through sunbeds and sunlamps has not changed. However psoralens and ultraviolet A radiation (PUVA) used for the treatment psoriasis and other inflammatory skin diseases has been implicated with the development of scrotal SCC[24,25]. In 1990 Stern reported on a prospective 12.3 year study in 892 men who had undergone ultraviolet radiation as part of their psoriasis treatment, out of which 14 developed genital tumor including 5 patients who developed 9 invasive scrotal SCC and one scrotal SCC in situ (SCCIS)[26]. They found that patients with high dose PUVA had 286 times the risk of the general population to develop invasive genital SCC, low dose PUVA had 16.3 times the risk and high dose UVB was associated with 4.6 times elevation of the risk[26]. Authors recommended genital protection for men undergoing UV radiation for treatment of skin diseases.

Increasing incidence of oropharyngeal SCC has been attributed to increasing prevalence of oral mucosal HPV[27,28]. HPV viral oncoproteins E5, E6 and E7 have an important role in carcinogenesis with p53 tumor suppressor gene and Rb oncogene being the major targets[29]. HPV infection in scrotal SCC has only been reported in a few case reports or small series[18,30-33]. Andrews *et al*[32] reported a total of 6 (42.9%) out of 14 cases were associated with HPV.

Matoso *et al*[18] reported on 29 patients with scrotal SCC and found high-risk HPV in 7 cases (24.1%) assessed by in-situ hybridization. These authors also reported p16 positivity and elevated Ki67 in HPV positive scrotal SCC. These cases were also more likely to display a basaloid or warty morphology. They suggested p16 stain to be used for screening for HPV infection with addition of Ki67 in cases with equivocal p16. If indeed the true proportion of HPV associated scrotal SCC lies between 24%-42% as in these small series, it has important implications for preventive therapy with the availability of HPV vaccines.

Chronic mechanical irritation has been associated with scrotal SCC. Long-term rubber urinal use[34], topical nitrogen mustard[35] and coal tar[36] have been reported to be associated with scrotal SCC in this manner. Initially scrotal SCC was thought to be uncommon among non-Caucasian ethnicities however subsequent reports in Africans, African Americans and other ethnicities including Chinese refuted this hypothesis[37,38].

Both preceding and subsequent increased malignancy risk has been described in patients with scrotal SCC[39]. Verhoeven reported 18% of patients with scrotal malignancy developed one or more tumors after the scrotal tumor with lung cancer, skin SCC and second scrotal tumor being the most common second malignancy[1].

**DIAGNOSIS**

The most common presentation of scrotal SCC is of an erythematous scrotal nodule or plaque[40]. Ulceration and pruritus often accompany the lesion. It occurs most commonly in the left scrotum, lower and anterior areas[40,41]. It can uncommonly present as abscess or ulcer[42]. The main differential diagnoses are extramammary Paget’s disease, verrucous carcinoma and bowenoid papulosis[43-46]. Pigmented scrotal SCC and scrotal SCCIS have been rarely reported[38,47]. Multiple scrotal SCCs in the same patient have often been described[26,48]. Table 1 lists the risk factors that have been associated with scrotal SCC.

**STAGING**

In 1983, Lowe modified the initial staging system proposed by Ray and Whitmore and this staging system is still in use as outlined in Table 2[49].

The American Joint committee on Cancer (AJCC), TNM classification for scrotal SCC is similar to TNM classification for SCC in other locations (with the exception of Eyelid, Vulva and Penis) and is shown in Table 3.

For staging clinical examination including the assessment of extension and depth of the scrotal lesion and examination of inguinal lymph nodes is mandatory. Plane chest X-ray for evaluation of the lungs is recommended. MRI scan and ultrasonography can be used for assessing the depth of the lesion and evidence of involvement of underlying structures where this is suspected. For inguinal lymph node imaging in general CT scan can detect enlarged inguinal and pelvic lymph nodes but is unable to identify small metastatic deposits in normal sized nodes. For nodal disease ultrasound and fine needle biopsy of suspicious lymph nodes similar to penile cancer might be of diagnostic value[50]. Similarly with improvement in sensitivity and specificity profile of 18F-FDG PET/CT might have a role in further staging of inguinal lymph nodes in patients with scrotal SCC[51]. For high-risk cases sentinel lymph node biopsy at the time of excision of primary lesion similar to penile cancer has been advocated[52].

**MANAGEMENT**

Few case series have been reported since 2000 (Table 4).

***Primary tumour***

Wide local excision of the lesion with a negative margin is the goal for the treatment of primary tumor. A surgical margin of 2-3 cm has been advocated by some authors[53], however the available guidelines for the management of cutaneous SCC recommend a 4mm radial margin for small (< 2 cm) lesions with well define edges and a radial margin of 6mm for larger lesions with poor defined edges and risk of subcutaneous extension[54]. Based on evidence from penile SCC, for < T2 disease a margin of ≥ 3 mm is considered safe where for ≥ T2 disease a surgical margin of 5-10mm is considered appropriate[55]. Given the redundancy and laxity of scrotal skin primary scrotal closure is usually possible, but after large tumor resection primary closure might not be achievable. The defect can be reconstructed with simple closure, flap, split thickness skin graft, mesh grafts or mycocutaneous grafts. Hemiscrotectomy is required for more advanced disease. Contralateral testicular transposition is an option if preservation of testis is preferable[56].

For patients with significant co-morbidities in whom surgical management is not suitable less invasive treatments such as CO2 laser for invasive SCC and 5-fluorouracil, photodynamic therapy or imiquimod for SCCIS may be considered[57,58]. Imiquimod has also been used as adjuvant to surgery post-excision[18]. Superficial small SCC and SCCIS are also amenable to mohs micrographic surgery which offers full evaluation of the surgical margins at the time of surgery and skin-sparing surgery with good functional and aesthetic outcomes[59,60]

.

***Inguinal lymph node***

Morley observed early on in the 20th century that the raphe of the scrotum does not provide a physical barrier to scrotal lymphatic drainage and the scrotum has bilateral inguinal drainage[61]. This observation forms the basis for bilateral inguinal assessment when treating patients with scrotal SCC. Data from early series suggest that similar to penile cancer only half of the patients with inguinal lymphadenopathy at the time of diagnosis, harbor metastatic disease at inguinal lymph node dissection (ILND) questioning the need for routine ILND dissection in patients with inguinal adenopathy[62]. The authors advocated a period of follow-up at (2-3 mo) after excision of primary lesion and ipsilateral ilioinguinal dissection if patient developed biopsy proven evidence of metastasis, and to defer contralateral node dissection until clinical verification of metastasis is evident.

The more contemporary algorithm for treatment of inguinal lymph node in patients with scrotal SCC has many similarities to patients with penile cancer[63]. A risk based approach to minimize morbidity associated with ILND advocates the use of inguinal sentinel lymph node biopsy[49], with subsequent complete ILND in cases where sentinel lymph node biopsy is positive[64]. Due to rarity of this condition data from large case series are lacking and the current recommendations are largely based on experts’ opinions and extrapolation of data from series with penile SCCs.

***Locally advanced and metastatic disease***

Adjuvant chemotherapy has been utilized in advanced stage and metastatic disease. Systemic chemotherapy is also indicated for inoperable scrotal SCC. Combination chemotherapy with methotrexate, bleomycin and cisplatin has been reported in inoperable or metastatic SCC of male genital tract with response rate of 72%, however median response duration was only 6 mo and only 14% achieved complete response[65]. Bleomycin has been utilized in the neoadjuvant setting. Adjuvant radiation has been shown to not change outcomes[32].

**EMERGING THERAPIES**

The era of targeted molecular and immunotherapies holds promise for management of advanced squamous cell carcinoma. Cetuximab an anti-epidermal growth factor receptor (EGFR) monoclonal antibody is an approved agent for treatment of head and neck SCC[66]. Emerging therapies for head and neck SCC include EGFR tyrosine kinase inhibitors, vascular endothelial growth factor receptor (VEGFR) inhibitors, insulin-like growth factor receptor (IGF-1R) inhibitors and inhibitors of the PI3K/AKT/mTOR pathway may have a role in the treatment of patients with scrotal SCC in future[67]. Unfortunately currently data on the efficacy of utility of such therapies for patients with scrotal SCC is lacking.

Recently Lavens *et al*[68] showed increased EGFR expression in penile SCC. Carthon *et al*[69] evaluated EGFR targeted therapy in patients with advanced penile or scrotal cancer in a retrospective case series of twenty-four patients. Only one of twenty-four patients had scrotal SCC. This patient developed metastases to right groin with disease progression despite paclitaxel, ifosfamide, and cisplatin (TIP) chemotherapy. The addition of EGFR targeted therapy lead to reduction in tumor burden and allowed resection of residual disease. He was reported to be disease free 38 mo post EGFR therapy.

Further studies need to focus on establishing EGFR status in scrotal SCC tissue before prospective evaluation of benefits of EGFR targeted therapies. Due to low incidence scrotal SCC, multi-institutional collaboration would be a more feasible approach. Further genomic and molecular characterization of scrotal SCC would be important in identifying key pathways and developing therapeutic targets.

**CONCLUSION**

Scrotal SCC is a rare clinical entity that represents one of the most common forms of scrotal malignancy. Although historically considered as an occupational disease, its epidemiology has changed in recent years and iatrogenic conditions (PUVA, Immunosuppression *etc.*) and HPV infection play a significant role as associating conditions. Surgery is the cornerstone of treatment algorithm for scrotal SCC. Excision of the primary lesion and risk stratified approach for staging and treatment of regional lymph node is advisable. For patients with high-risk disease and negative clinical lymph nodes, sentinel lymph node biopsy can mitigate the morbidities of unwarranted ILND. For locally advanced and metastatic disease palliative chemotherapy is advocated. Future endeavors with focus on targeted therapies might hold promise for management of advanced squamous cell carcinoma. Given the rarity of this condition, multi-institutional trials in conjunction with trials for the treatment of penile SCC are likely to provide us with further knowledge in this field.

**REFERENCES**

1 **Verhoeven RH**, Louwman WJ, Koldewijn EL, Demeyere TB, Coebergh JW. Scrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989. *Br J Cancer* 2010; **103**: 1462-1466 [PMID: 20877361 DOI: 10.1038/sj.bjc.6605914]

2 **Wright JL**, Morgan TM, Lin DW. Primary scrotal cancer: disease characteristics and increasing incidence. *Urology* 2008; **72**: 1139-1143 [PMID: 18799208 DOI: 10.1016/j.urology.2008.06.043]

**3** **Graves** RC, Flo S. Carcinoma of the scrotum. J Urol 1940; **43:** 309–332

4 **Waterhouse JA**. Subsequent malignancy in environmental scrotal cancers. *Proc R Soc Med* 1977; **70**: 111-112 [PMID: 558614]

5 **Kipling MD**, Waldron HA. Percivall Pott and cancer scroti. *Br J Ind Med* 1975; **32**: 244-246 [PMID: 1098690]

6 **Doll R**. Part III: 7th Walter Hubert lecture. Pott and the prospects for prevention. *Br J Cancer* 1975; **32**: 263-272 [PMID: 764848 DOI: 10.1038/bjc.1975.212]

7 **Jackson R**. Early clinical descriptions of skin cancer. *Can Med Assoc J* 1973; **109**: 906-908 [PMID: 4584333]

8 **Hodgson GA**, Whiteley HJ. Personal susceptibility to pitch. *Br J Ind Med* 1970; **27**: 160-166 [PMID: 4246788]

9 **Lee WR**, McCann JK. Mule spinners' cancer and the wool industry. *Br J Ind Med* 1967; **24**: 148-151 [PMID: 6071507]

10 **Kipling MD**. Oil and cancer. *Ann R Coll Surg Engl* 1974; **55**: 71-79 [PMID: 4858528]

11 **Fay HT**. Risk factors in scrotal epithelioma. *J R Soc Med* 1978; **71**: 741-747 [PMID: 712728]

12 **HENRY SA**. Occupational cutaneous cancer attributable to certain chemicals in industry. *Br Med Bull* 1947; **4**: 389-401 [PMID: 20240897]

13 **Angulo JC**, López JI, Flores N. Squamous cell carcinoma of the scrotum in an aluminium worker. *Postgrad Med J* 1993; **69**: 960-961 [PMID: 8121880 DOI: 10.1136/pgmj.69.818.960-a]

14 **Doll R**, Vessey MP, Beasley RW, Buckley AR, Fear EC, Fisher RE, Gammon EJ, Gunn W, Hughes GO, Lee K, Norman-Smith B. Mortality of gasworkers - final report of a prospective study. *Br J Ind Med* 1972; **29**: 394-406 [PMID: 15625750]

15 **Cruickshank CN**, Squire JR. Skin cancer in the engineering industry from the use of mineral oil. *Br J Ind Med* 1950; **7**: 1-11 [PMID: 15403146]

16 **Johnson TV**, Hsiao W, Delman KA, Canter DJ, Master VA. Scrotal cancer survival is influenced by histology: a SEER study. *World J Urol* 2013; **31**: 585-590 [PMID: 22418823 DOI: 10.1007/s00345-012-0834-0]

17 **Stern RS**, Bagheri S, Nichols K. The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. *J Am Acad Dermatol* 2002; **47**: 33-39 [PMID: 12077578]

18 **Matoso A**, Ross HM, Chen S, Allbritton J, Epstein JI. Squamous neoplasia of the scrotum: a series of 29 cases. *Am J Surg Pathol* 2014; **38**: 973-981 [PMID: 24618607]

19 **Seabra D**, Fava G, Faria E, Sacheto T, Hidalgo G. Scrotal neoplasia: would truck drivers be at greater risk? *Int Braz J Urol* 2007; **33**: 515-59; discussion 520 [PMID: 17767756]

20 **Kickham CJ**, Dufresne M. An assessment of carcinoma of the scrotum. *J Urol* 1967; **98**: 108-110 [PMID: 6067877]

21 **Parys BT**, Hutton JL. Fifteen-year experience of carcinoma of the scrotum. *Br J Urol* 1991; **68**: 414-417 [PMID: 1933164 DOI: 10.1111/j.1464-410X.1991.tb15363.x]

22 **Roush GC**, Schymura MJ, Flannery JT. Secular and age distribution of scrotal cancer in Connecticut and a review of United States literature. *Cancer* 1984; **54**: 596-601 [PMID: 6733690 DOI: 10.1002/1097-0142(19840801)54: 3<596: : AID-CNCR2820540335>3.0.CO; 2-J]

23 **Goldoft MJ**, Weiss NS. Incidence of male genital skin tumors: lack of increase in the United States. *Cancer Causes Control* 1992; **3**: 91-93 [PMID: 1536920]

24 **Loughlin KR**. Psoriasis: association with 2 rare cutaneous urological malignancies. *J Urol* 1997; **157**: 622-623 [PMID: 8996374 DOI: 10.1016/S0022-5347(01)65222-4]

25 **Taniguchi S**, Furukawa M, Kutsuna H, Sowa J, Ishii M. Squamous cell carcinoma of the scrotum. *Dermatology* 1996; **193**: 253-254 [PMID: 8944352 DOI: 10.1159/000246258]

26 **Stern RS**. Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. *N Engl J Med* 1990; **322**: 1093-1097 [PMID: 2320078 DOI: 10.1056/NEJM199004193221601]

27 **Shaw R**, Robinson M. The increasing clinical relevance of human papillomavirus type 16 (HPV-16) infection in oropharyngeal cancer. *Br J Oral Maxillofac Surg* 2011; **49**: 423-429 [PMID: 20727631 DOI: 10.1016/j.bjoms.2010.06.023]

28 **Panwar A**, Batra R, Lydiatt WM, Ganti AK. Human papilloma virus positive oropharyngeal squamous cell carcinoma: a growing epidemic. *Cancer Treat Rev* 2014; **40**: 215-219 [PMID: 24080155 DOI: 10.1016/j.ctrv.2013.09.006]

29 **Mighty KK**, Laimins LA. The role of human papillomaviruses in oncogenesis. *Recent Results Cancer Res* 2014; **193**: 135-148 [PMID: 24008297 DOI: 10.1007/978-3-642-38965-8\_8]

30 **Orihuela E**, Tyring SK, Pow-Sang M, Dozier S, Cirelli R, Arany I, Rady P, Sanchez R. Development of human papillomavirus type 16 associated squamous cell carcinoma of the scrotum in a patient with Darier's disease treated with systemic isotretinoin. *J Urol* 1995; **153**: 1940-1943 [PMID: 7752363 DOI: 10.1097/00005392-199506000-00064]

31 **Güran S**, Pak I. Cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal cancer. *Cancer Genet Cytogenet* 1999; **109**: 108-113 [PMID: 10087941 DOI: 10.1016/S0165-4608(98)00155-1]

32 **Andrews PE**, Farrow GM, Oesterling JE. Squamous cell carcinoma of the scrotum: long-term followup of 14 patients. *J Urol* 1991; **146**: 1299-1304 [PMID: 1942281]

33 **Burmer GC**, True LD, Krieger JN. Squamous cell carcinoma of the scrotum associated with human papillomaviruses. *J Urol* 1993; **149**: 374-377 [PMID: 8381191]

34 **Grundy D**, Jones AC, Powley PH. Carcinoma of the scrotum associated with rubber urinals. Case report. *Paraplegia* 1993; **31**: 616-617 [PMID: 8247605 DOI: 10.1038/sc.1993.98]

35 **Lee LA**, Fritz KA, Golitz L, Fritz TJ, Weston WL. Second cutaneous malignancies in patients with mycosis fungoides treated with topical nitrogen mustard. *J Am Acad Dermatol* 1982; **7**: 590-598 [PMID: 7142467 DOI: 10.1016/S0190-9622(82)70138-0]

36 **Moy LS**, Chalet M, Lowe NJ. Scrotal squamous cell carcinoma in a psoriatic patient treated with coal tar. *J Am Acad Dermatol* 1986; **14**: 518-519 [PMID: 3958269 DOI: 10.1016/S0190-9622(86)80436-4]

37 **Oluwasanmi JO**, Williams AO, Alli AF. Superficial cancer in Nigeria. *Br J Cancer* 1969; **23**: 714-728 [PMID: 5367332 DOI: 10.1038/bjc.1969.88]

38 **Wagner RF**, Grande DJ. Solitary pigmented Bowen's disease of the scrotum. *J Dermatol Surg Oncol* 1986; **12**: 1114-1115 [PMID: 3760318 DOI: 10.1111/j.1524-4725.1986.tb02091.x]

39 **Gerber WL**. Scrotal malignancies: the University of Iowa experience and a review of the literature. *Urology* 1985; **26**: 337-342 [PMID: 2996197 DOI: 10.1016/0090-4295(85)90179-7]

40 **McDonald MW**. Carcinoma of scrotum. *Urology* 1982; **19**: 269-274 [PMID: 7064253 DOI: 10.1016/0090-4295(82)90497-6]

41 **Southam AH**, Wilson SR. Cancer of the scrotum: The Etiology, Clinical Features, and Treatment of the Disease. *Br Med J* 1922; **2**: 971-970.1 [PMID: 20770922]

42 **Huen KH**, Nourparvar P, Decaro JJ, Walsh MD, Issa MM, Ritenour CW. Scrotal abscess as initial presentation of squamous cell carcinoma. *Case Rep Urol* 2013; **2013**: 807346 [PMID: 24102031]

43 **Du X**, Yin X, Zhou N, Zhang G, Shi H, Cao S. Extramammary Paget's disease mimicking acantholytic squamous cell carcinoma in situ: a case report. *J Cutan Pathol* 2010; **37**: 683-686 [PMID: 19615013 DOI: 10.1111/j.1600-0560.2009.01336.x]

44 **Miyakawa T**, Togawa Y, Matushima H, Nakamura H, Kamada N, Momota Y, Tochigi N, Nikaido T, Shinkai H, Utani A. Squamous metaplasia of Paget's disease. *Clin Exp Dermatol* 2004; **29**: 71-73 [PMID: 14723727 DOI: 10.1111/j.1365-2230.2004.01425.x]

45 **Criton S**, Aravindan KP. Bowenoid papulosis turning to squamous cell carcinoma. *Indian J Dermatol Venereol Leprol* 1998; **64**: 37-39 [PMID: 20921709]

46 **Quinn AM**, Sienko A, Basrawala Z, Campbell SC. Extramammary Paget disease of the scrotum with features of Bowen disease. *Arch Pathol Lab Med* 2004; **128**: 84-86 [PMID: 14692806]

47 **Matsumoto M**, Sonobe H, Takeuchi T, Furihata M, Iwata J, Ikeda M, Ohtsuki Y. Pigmented squamous cell carcinoma of the scrotum associated with a lentigo. *Br J Dermatol* 1999; **141**: 132-136 [PMID: 10417529 DOI: 10.1046/j.1365-2133.1999.02934.x]

48 **Yamaoka H**, Ikoma N, Kato M, Akasaka E, Tamiya S, Matsuyama T, Ozawa A, Fukunaga Y. Multiple Bowen's disease in a patient with a history of possible arsenic exposure: a case report. *Tokai J Exp Clin Med* 2011; **36**: 53-57 [PMID: 21769774]

49 **Lowe FC**. Squamous cell carcinoma of the scrotum. *J Urol* 1983; **130**: 423-427 [PMID: 6350613]

50 **Djajadiningrat RS**, Teertstra HJ, van Werkhoven E, van Boven HH, Horenblas S. Ultrasound examination and fine needle aspiration cytology-useful for followup of the regional nodes in penile cancer? *J Urol* 2014; **191**: 652-655 [PMID: 23994372 DOI: 10.1016/j.juro.2013.08.046]

51 **Rosevear HM**, Williams H, Collins M, Lightfoot AJ, Coleman T, Brown JA. Utility of ¹⁸F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes. *Urol Oncol* 2012; **30**: 723-726 [PMID: 21396850 DOI: 10.1016/j.urolonc.2010.09.015]

52 **Greene TD**, Abrahams HM, Moran ME. Dynamic lymphoscintigraphy for staging scrotal carcinoma. *J Urol* 2001; **165**: 536-537 [PMID: 11176424 DOI: 10.1097/00005392-200102000-00054]

53 **Azike JE**. A review of the history, epidemiology and treatment of squamous cell carcinoma of the scrotum. *Rare Tumors* 2009; **1**: e17 [PMID: 21139888]

54. **Motley R**, Kersey P, Lawrence C; British Association of Dermatologists; British Association of Plastic Surgeons. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Plast Surg. 2003 Mar;56(2):85-91. [PMID: 12791348]

55 **Minhas S**, Kayes O, Hegarty P, Kumar P, Freeman A, Ralph D. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? *BJU Int* 2005; **96**: 1040-1043 [PMID: 16225525 DOI: 10.1111/j.1464-410X.2005.05769.x]

56 **Arango O**, Bielsa O, Lorente JA, De Leon E, Mas AG. Hemiscrotectomy with contralateral testicular transposition for scrotal cancer. *J Urol* 2002; **168**: 1406-1407 [PMID: 12352404 DOI: 10.1097/00005392-200210010-00024]

57 **Rosemberg SK**. Lasers and squamous cell carcinoma of external genitalia. *Urology* 1986; **27**: 430-433 [PMID: 3705277 DOI: 10.1016/0090-4295(86)90408-5]

58 **Bath-Hextall FJ**, Matin RN, Wilkinson D, Leonardi-Bee J. Interventions for cutaneous Bowen's disease. *Cochrane Database Syst Rev* 2013; **6**: CD007281 [PMID: 23794286]

59 **Wells MJ**, Taylor RS. Mohs micrographic surgery for penoscrotal malignancy. *Urol Clin North Am* 2010; **37**: 403-409 [PMID: 20674695 DOI: 10.1016/j.ucl.2010.04.012]

60 **Brown MD**, Zachary CB, Grekin RC, Swanson NA. Genital tumors: their management by micrographic surgery. *J Am Acad Dermatol* 1988; **18**: 115-122 [PMID: 3346395 DOI: 10.1016/S0190-9622(88)70017-1]

61 **Morely J.** The lymphatics of the scrotum. *Lancet* 1911; **1:** 1545-1547. doi:10.1016/S0140-6736(00)40413-7

62 **Ray B**, Whitmore WF. Experience with carcinoma of the scrotum. *J Urol* 1977; **117**: 741-745 [PMID: 559784]

63 **Pizzocaro G**, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, Watkin NA. EAU penile cancer guidelines 2009. *Eur Urol* 2010; **57**: 1002-1012 [PMID: 20163910 DOI: 10.1016/j.eururo.2010.01.039]

64 **Lowe FC**. Squamous-cell carcinoma of the scrotum. *Urol Clin North Am* 1992; **19**: 397-405 [PMID: 1574830]

65 **Dexeus FH**, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. *J Urol* 1991; **146**: 1284-1287 [PMID: 1719241]

66 **Cohen RB**. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). *Cancer Treat Rev* 2014; **40**: 567-577 [PMID: 24216225 DOI: 10.1016/j.ctrv.2013.10.002]

67 **Dorsey K**, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. *Drugs* 2013; **73**: 315-325 [PMID: 23440867 DOI: 10.1007/s40265-013-0025-3]

68 **Lavens N**, Gupta R, Wood LA. EGFR overexpression in squamous cell carcinoma of the penis. *Curr Oncol* 2010; **17**: 4-6 [PMID: 20179797]

69 **Carthon BC**, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. *BJU Int* 2014; **113**: 871-877 [PMID: 24053151 DOI: 10.1111/bju.12450]

**P-Reviewer:** Fernandez-Pello S **S-Editor:** Ji FF **L-Editor: E-Editor:**

|  |
| --- |
| Table 1 Risk factors associated with scrotal squamous cell carcinoma |
| Occupations |
| Chimney sweepers, tar and paraffin workers, occupations with exposure to mineral and cutting oils, printing, metal working,car and aeroplane manufacture, car mechanics, commercial printing, aluminum worker, shale oil workers, pitch workers, engineering, steel production, cavalrymen |
| Carcinogenic metals |
| Arsenic, nickel, chromium |
| Chronic mechanical irritation |
| Chronic inflammatory states |
| Chronic lymphedema, infective and surgical scars |
| Lifestyle |
| Poor personal hygiene, smoking |
| Viruses |
| HPV |
| Ionizing Radiation |
| Iatrogenic |
| Coal tar, PUVA, radiotherapy, nitrogen mustard, Fowler’s solution |
| Immunosuppression |
| Acquired and inherited immunodeficiency, post transplant immunosuppression |

HPV: Human papilloma virus; PUVA: Psoralens and ultraviolet A radiation.

|  |  |
| --- | --- |
| Table 2 Lowe’s staging of scrotal squamous cell carcinoma | |
| A1 | Disease localized to scrotum |
| A2 | Locally extensive disease involving adjacent structures (penis, perineum, testis or cord, and pubic bone) by continuity but without evident metastasis |
| B | Superficial lymph node metastasis, resectable |
| C | Pelvic lymph node metastasis or any unresectable metastasis |
| D | Distant metastasis beyond regional nodes |

|  |  |  |  |
| --- | --- | --- | --- |
| Table 3 TNM staging system for squamous cell carcinoma | | | |
| Stage | **Primary tumour** | **Regional lymph nodes** | **Distant metastasis** |
| Stage 0 | Tis = carcinoma in situ | N0 = no regional lymph node involvement | M0 |
| Stage I | T1 = tumour 2 cm or less | N0 | M0 |
| Stage II | T2 = tumour > 2 cm but < 5 cm | N0 | M0 |
|  | T3 = tumour > 5 cm | N0 | M0 |
| Stage III | T4 = Invasion of deeper extradermal structures | N0 | M0 |
|  | Any T | N1 = regional lymph node spread. | M0 |
| Stage IV | Any T | Any N | M1 = distant metastasis. |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Table 4 Case series with epidemiology, management and outcomes of scrotal squamous cell carcinoma published after 2000 | | | | |
| Ref. | **N** | **Design** | **Cohort characteristics** | **Summary** |
| Stern *et al*[17]  (2002) | 17 | Prospective multi-institutional cohort study | 892 men first treated with PUVA | Dose-dependent increase in the risk of genital tumors in men treated with PUVA |
| Seabra *et al*[19]  (2007) | 6 | Retrospective single institution | **Age**: 52 (31-89)  **Race**: Ca: 2; Bl: 2; Oth: 1; Unknown: 1  **Staging**: LC: 4, RL: 1, DD: 1 | 4/6 WLE; 1/6 WLE + SLNB; 1/6 was unresectable:  1 developed LN metastasis and was treated with chemo/radiation  Patient with unresectable disease and was treated with chemotherapy and subsequently died |
| Wright *et al*[2]  (2008) | 151 | SEER (1973-2002) | **Age**: 682  **Race**: Ca 117 (77.5); Bl 24 (15.9); Oth 10 (6.6) | SCC had the worse survival compared to other histological subtypes |
| Verhoeven *et al*[1] (2010) | 53 | NCR (1989-2006) | **Age**: 56.5  **Staging:** Stg 0: 1 (1.9), Stg 1: 22 (41.5), Stg 2: 18 (34), Stg 3: 2 (3.8), Stg 4: 0, Unk: 10 (18.9) | SCC had the worse survival compared to other histological subtypes:  1 Yr relative survival 93%  3 Yr relative survival 80%  5 Yr relative survival 77% |
| Johnson *et al*[16]  (2013) | 269 | SEER (1973-2006) | **Age**: 65.42 ± 14.9  **Race**: Ca 206 (76.6%), Bl 43 (16.0%), As 12 (4.5%), Hi 18 (6.7%), Oth 8 (3.0%)  **Staging**: LC 205 (76.2%), RL 54 (20.1%), DD 10 (3.7%) | The median OS for patients with SCC was 115 (95%CI: 97-133) mo. |
| Matoso *et al*[18] (2014) | 29 | Retrospective multi-institutional | **Age**: 55 (30-74)  **Race:** Ca 19 (65.5%), Bl 10 (34.5%)  **Follow up:** 37 mo. | 25/29 WLE; 1/29 WLE + LND; 3/29 imiquimod post WLE:  13 (45%) with1 margins required re-excision1  3/29 local recurrence: 2 WLE; 1 WLE/RT  3 /29 with lymphadenopathy lost to follow-up |

1Positive; 2Mean. As: Asian; Bl: Black,; Ca: Caucasians; DD: Distant disease; Hi: Hispanics; LC: Local disease; Mo.: Months; NCR: Netherlands Cancer Registry; OS: Overall survival; Oth: Other; PUVA: Psoralens and ultraviolet A radiation; RL: Regional lymph node; SCC: Squamous cell carcinoma; SEER: Surveillance, Epidemiology and end results; SLNB: Sentinel lymph node biopsy; Stg: Stage; WLE: Wide local excision; Yr: Year.